S&P 500 Financials Sector SEC Filings — June 10, 2026

10-06-2026

Purebase Corporation announced the appointment of Dr. Amy T. Clemens as Chief Financial Officer, effective June 5, 2026. Dr. Clemens previously served as interim CFO for two years during the company's inception and returns from the defense industry. The filing does not disclose any financial metrics or performance data, so no period-over-period comparisons or quantitative trends are available.

• · Dr. Clemens previously served as interim CFO for 2 years during Purebase's inception before returning to the defense industry.
• · The appointment is effective June 5, 2026.
• · The company describes itself as a 'highly diversified mineral resource company' and a 'diversified resource company' that acquires, develops and markets high-value minerals and agricultural products.

10-06-2026

Vanguard Green Investment Ltd reported zero revenue for the three and nine months ended April 30, 2026, with net losses widening to $19,062 (Q3) and $66,191 (nine months) compared to $11,146 and $40,251 in the prior-year periods. The company's accumulated deficit increased to $2,627,012 and total stockholders' deficit deepened to $790,769, while cash and cash equivalents fell to just $55 from $93 at July 31, 2025. The company continues to rely on director loans ($57,749 in financing during the nine months) to fund operations, with no revenue-generating activities reported.

• · Revenue remained zero for all periods reported, with no cost of revenue or gross profit.
• · Other income was $0 for the three and nine months ended April 30, 2026, compared to $832 and $875 in the prior-year periods.
• · Selling and marketing expenses were $0 for all periods.
• · Income tax provision was $0 for all periods.
• · No foreign currency translation loss was recorded.
• · Net loss per share (basic and diluted) was $(0.0003) for Q3 2026 vs $(0.0002) for Q3 2025, and $(0.0011) vs $(0.0007) for the nine-month periods.
• · Weighted average shares outstanding remained constant at 59,434,838.
• · Property, plant and equipment was fully depreciated and impaired to $0 as of both balance sheet dates.
• · Patent and trademark intangible asset was $0.
• · Total assets increased slightly from $15,258 to $16,555, driven by a rise in prepayments.
• · Total liabilities increased from $739,836 to $807,324, primarily due to higher director and third-party loans.
• · The company had no preferred stock issued or outstanding.
• · Cash used in operating activities increased to $57,787 from $43,981 (nine months).
• · The company's only source of cash from financing was director loans.
• · The company's cash balance at period end was only $55, indicating severe liquidity constraints.

10-06-2026

Toyota Motor Corp reported total vehicle sales of 9,595,000 units for the fiscal year ended March 31, 2026, up 2.5% from 9,362,000 units in the prior year, driven by strong growth in North America (+8.5%) and Japan (+4.6%). However, sales in Asia declined 4.3% to 1,759,000 units, and the 'Other' region slipped 1.3% to 1,637,000 units. Operating income decreased by ¥1,029,300 million year-over-year, primarily due to a ¥2,030,000 million increase in expenses, partially offset by ¥710,000 million in marketing gains.

• · Toyota's Japan market share (excluding mini-vehicles) was 50.9% in FY26, up from 50.4% in FY25 but down from 51.8% in FY24.
• · In North America, Toyota's market share rose to 15.1% in calendar 2025 from 14.4% in 2024 and 14.3% in 2023.
• · In Europe, Toyota's market share slipped to 6.6% in calendar 2025 from 6.8% in 2024.
• · In Asia (excluding China), Toyota's market share was 13.0% in calendar 2025, down from 13.1% in 2024.
• · Capital expenditures included ¥1,915.2 billion in Japan by Toyota Motor Corporation, ¥730.6 billion for Toyota Battery Manufacturing in the U.S., and ¥7,032.5 billion for leased automobiles by Toyota Motor Credit Corporation.
• · Toyota holds a 90.00% ownership interest in Toyota Battery Manufacturing, Inc. and Toyota Motor Manufacturing Turkey Inc., and 86.43% in Toyota Motor Thailand Co., Ltd.
• · Toyota Woven City, a research and development facility, has only 8 employees.
• · The operating income decline of ¥1,029,300 million was driven by a ¥2,030,000 million increase in expenses, partially offset by ¥710,000 million in marketing efforts and ¥605,700 million in other gains.

10-06-2026

Paramount Skydance Corporation (PSKY) announced on June 9, 2026, that the Australian Competition and Consumer Commission (ACCC) has approved its pending merger with Warner Bros. Discovery (WBD), subject to a 14-day waiting period expiring June 23, 2026. Additionally, the New Zealand Commerce Commission indicated it will not consider the merger further, and approvals have been received from competition authorities in Saudi Arabia, Ukraine, Serbia, and North Macedonia, as well as foreign investment authorities in Germany, Slovenia, Belgium, Czechia, New Zealand, Italy, France, and Romania. However, the merger remains subject to other closing conditions and regulatory clearances, and the company warns that material risks—including failure to obtain remaining antitrust approvals, integration challenges, substantial debt, and ongoing litigation—could cause actual results to differ materially from forward-looking statements.

• · Australian ACCC concluded the merger is unlikely to substantially lessen competition in wholesale film supply for theatrical release in Australia.
• · ACCC noted the merged entity would continue to be constrained by other film studios post-acquisition and that Paramount and Warner Bros. are not particularly close competitors.
• · New Zealand Commerce Commission informed PSKY on June 5, 2026, that it does not intend to consider the merger further under its voluntary clearance regime.
• · Regulatory approvals obtained from Saudi Arabia, Ukraine, Serbia, North Macedonia (competition authorities) and from Germany, Slovenia, Belgium, Czechia, New Zealand, Italy, France, and Romania (foreign direct investment authorities).
• · The Merger Agreement was entered into on February 27, 2026, with Merger Sub merging into WBD, which will survive as a wholly owned subsidiary of PSKY.
• · The Australian waiting period is scheduled to expire at 10:00 a.m. Eastern Time on June 23, 2026.
• · Key risks highlighted include failure to obtain remaining regulatory clearances, integration difficulties, employee departures, stockholder litigation, substantial debt, and potential inability to deleverage as planned.

10-06-2026

Elevance Health reaffirmed its full-year 2026 guidance, expecting at least $19.85 per diluted share in reported shareholders' earnings, including approximately $6.90 per diluted share of net unfavorable items. Excluding these items, the company maintains its outlook for adjusted shareholders' earnings of at least $26.75 per diluted share, and reaffirmed the full-year 2026 benefit expense ratio guidance of 90.2% plus or minus 50 basis points. No period-over-period comparisons or new financial results were provided in this filing.

10-06-2026

Corebridge Financial, Inc. (CRBG) provided an update on its merger with Equitable Holdings, Inc., announcing progress on leadership appointments and integration planning, with the transaction expected to close by end of 2026. The combined entity will create a full-scale retirement platform with $90+ billion in assets moving to AllianceBernstein, making it a $1 trillion platform, and is expected to be accretive day one with double-digit accretion by 2029. However, the company faces near-term headwinds from market volatility and lower alternative investment returns, with VII expected to be roughly consistent with Q1 2025 levels and full-year returns in the 1-2% range, below long-term expectations.

• · Leadership first three layers announced; wave two communications expected in coming weeks.
• · Proxy and regulatory filings completed domestically and internationally; FINRA process in flight.
• · Expense synergy pacing: 30% by end of year 1, 75% by end of year 2, remainder shortly after.
• · Revenue synergies include cross-selling Corebridge's fixed annuities and IUL through Equitable's wealth management channel and Equitable's VUL through Corebridge distribution.
• · Nippon Life will own over 15% of the new Equitable, with potential to partner on spread products for Japan.
• · Corebridge's 2025 origination of $55B was split equally among internal capabilities, BlackRock, and Blackstone.
• · Near-term headwinds include market volatility, geopolitical uncertainty, and disruptions in software and private credit.
• · Q2 2026 alternative returns expected lower than Q1 2026; VII expected roughly consistent with Q1 2026.
• · Full-year VII expected in 1-2% range, below long-term expectations.

10-06-2026

InMed Pharmaceuticals Inc. regained compliance with Nasdaq's minimum $1.00 bid price requirement after its closing bid price remained at or above $1.00 for 10 consecutive business days from May 19 to June 2, 2026. The company had previously received a deficiency notice on March 27, 2026, due to its share price falling below the threshold for 30 consecutive trading days. Nasdaq confirmed the matter is now closed, removing the immediate delisting risk.

• · The deficiency notice was received on March 27, 2026, covering the period from February 11, 2026 to March 26, 2026.
• · Compliance was regained as of June 3, 2026, based on the 10 business days ending June 2, 2026.
• · A press release announcing the compliance was issued on June 4, 2026.

10-06-2026

Forward Industries, Inc. (FWDI) announced a non-binding proposal to acquire Brera Holdings PLC (SLMT) in an all-stock transaction, offering 1.54 FWDI shares per SLMT share, representing a ~30.7% premium to SLMT's VWAP. However, SLMT's board rejected the proposal on June 6, 2026, stating it is not in the company's best interest, and Forward has until July 21, 2026 to announce a firm offer or withdraw.

• · Forward Industries has assembled the largest Solana treasury in the world since launching its treasury strategy in September 2025.
• · Forward has staked the majority of its SOL to its high-performance validator infrastructure and begun deploying capital into Solana protocols.
• · The proposal is governed by the Irish Takeover Rules; Forward must announce a firm intention to make an offer or withdraw by 5:00pm New York time on July 21, 2026.
• · SLMT's board rejected the proposal on June 6, 2026, citing it is not in the best interest of the company.

10-06-2026

General Fusion Inc. was named the World's Top GreenTech Company of 2026 by TIME, highlighting its progress toward commercial fusion energy. The recognition comes as General Fusion advances its proposed business combination with Spring Valley Acquisition Corp. III (NASDAQ: SVAC) to become a publicly listed company. The company's LM26 fusion demonstration machine is now in operation, aiming to achieve key technical milestones, but the transaction remains subject to regulatory approvals and shareholder votes, with no guaranteed completion timeline.

• · General Fusion was established in 2002 and is headquartered in Vancouver, Canada.
• · LM26 mechanically compresses plasma with a lithium liner at 50% commercial-scale diameter.
• · LM26 aims to achieve plasma heating to 1 keV (10 million degrees Celsius), then 10 keV (100 million degrees Celsius), and ultimately the Lawson criterion for net fusion energy.
• · Spring Valley I completed a business combination with NuScale Power Corporation (SMR technology).
• · Spring Valley II completed a business combination with Eagle Nuclear Energy Corp. (uranium deposit rights).
• · The proposed business combination involves SVAC continuing from Cayman Islands to British Columbia, amalgamation of NewCo with General Fusion, and name change to 'General Fusion Group Ltd.'
• · The filing includes forward-looking statements and risk factors related to the business combination, including potential failure to complete, regulatory approvals, and LM26 program risks.

10-06-2026

On May 13, 2026, Ensign Group's Board approved a new stock repurchase program authorizing up to $40 million in common stock repurchases, to commence after the current program expires. Repurchases may occur in open market or private transactions and depend on market conditions and other factors.

• · The program will commence following expiration of the current stock repurchase program.
• · Repurchases may be made under Rule 10b-18 and Rule 10b5-1 plans.
• · The program may be modified, suspended, or discontinued at any time.

10-06-2026

Keel Infrastructure Corp. (NASDAQ/TSX: KEEL), the successor to Bitfarms Ltd., closed a $458 million offering of 1.250% convertible senior notes due 2032, generating approximately $445.4 million in net proceeds. A portion of the proceeds funded capped call transactions to offset dilution up to a share price of $11.86, while the remainder will support general corporate purposes including data center development. However, the company has a limited operating history with losses, faces risks from its strategic pivot from Bitcoin mining to HPC infrastructure, and the notes carry a low 1.250% coupon, indicating potential credit risk.

• · The convertible notes mature on January 15, 2032, unless earlier repurchased, redeemed, or converted.
• · Interest is payable semi-annually on January 15 and July 15, beginning January 15, 2027.
• · The initial conversion price is approximately $7.41 per share, a 25% premium over the June 4, 2026 closing price of $5.93.
• · The capped call cap price is $11.86 per share, a 100% premium over the same closing price.
• · Keel may settle conversions in cash, common stock, or a combination, at its election.
• · The notes were offered only to qualified institutional buyers under Rule 144A and exempt from Canadian prospectus requirements.
• · Keel relies on TSX Section 602.1 exemption for eligible interlisted issuers.
• · On April 1, 2026, Keel became the ultimate parent of Bitfarms via a statutory plan of arrangement, effectively redomiciling Bitfarms from Canada to the U.S.
• · The company has a 2.2 GW pipeline of digital infrastructure with grid interconnections in Pennsylvania, Washington, and Québec.
• · Forward-looking statements highlight risks including limited operating history, losses, strategic pivot to HPC, reliance on third-party suppliers, Bitcoin price volatility, and potential dilution from note conversion.

10-06-2026

iShares Bitcoin Premium Income ETF (ticker BITA) filed an S-1/A registration statement on June 9, 2026, to offer shares representing fractional undivided beneficial interests in a trust that invests in bitcoin, IBIT shares, and cash, while generating monthly premium income through covered call options on IBIT shares. The trust will use the CF Benchmarks Index for bitcoin valuation, has a sponsor fee of 0.65% annually, and will list on NASDAQ. However, the trust must sell bitcoin and/or IBIT shares to pay the sponsor fee and expenses not assumed by the sponsor, which will decrease the amount of assets per share over time, and it does not engage in profit-seeking activities beyond the option strategy.

• · The trust will issue and redeem baskets on a continuous basis, generally for all-cash deposits and partial cash redemptions.
• · The intraday indicative value (IIV) will be updated every 15 seconds during NASDAQ's regular market session (9:30 a.m. to 4:00 p.m. ET).
• · The trust may incur extraordinary expenses not assumed by the sponsor, including taxes, brokerage commissions, Bitcoin network fees, and options trading fees.
• · The trust may come into possession of Incidental Rights or IR Digital Assets from bitcoin forks or airdrops.
• · The trust has opted out of the extended transition period for complying with new or revised accounting standards under the JOBS Act.
• · The trust's sponsor fee is payable at least quarterly in arrears in U.S. dollars or in-kind.
• · The trust intends to pay the sponsor fee with proceeds from the sale of IBIT shares.

10-06-2026

Silver Bull Resources, Inc. announced on June 1, 2026 that its arbitration case against Mexico has been dismissed in its entirety by an ICSID tribunal, which concluded it lacked jurisdiction and/or the claim was time-barred. The company has been ordered to pay approximately US$998,000 of Mexico's legal costs. Silver Bull is assessing grounds for annulment (with 120 days to register) and evaluating strategic options, including seeking resolution of the ongoing blockade of its Sierra Mojada property or identifying other exploration projects.

• · The arbitration hearing was held in Washington, D.C. in October 2025.
• · Silver Bull submitted its post-hearing brief on November 21, 2025 and its costs on December 5, 2025.
• · The final award was rendered on May 29, 2026.
• · The company has 120 days from the ruling to register for annulment, and the proceeding would take approximately 18 to 36 months.
• · The arbitration arose from Mexico's expropriation and other treatment related to the blockade of the Sierra Mojada property.

10-06-2026

Pantages Capital Acquisition Corp (PGACU) filed an 8-K on June 10, 2026, announcing proposed amendments to its Third Amended and Restated Memorandum and Articles of Association to extend the deadline to complete a business combination. The proposal allows up to 12 monthly extensions from June 6, 2026, to June 6, 2027, providing a total of up to 30 months post-IPO. If no business combination is completed by the final deadline, the company will redeem public shares and dissolve.

• · The extension period runs from June 6, 2026 to June 6, 2027.
• · The company may extend up to 12 times, each by one month, for a total of up to 12 additional months.
• · If no business combination is completed by June 6, 2027, the company must cease operations, redeem public shares, and liquidate and dissolve.
• · Up to $100,000 of trust interest may be used for dissolution expenses before redemption proceeds are distributed to public shareholders.
• · Redemption price equals the aggregate amount in the trust account (including interest not previously released, less taxes and dissolution expenses) divided by the number of public shares outstanding.

10-06-2026

Aldeyra Therapeutics appointed Darlene Deptula-Hicks to its board of directors on June 9, 2026. Ms. Deptula-Hicks brings over 30 years of experience in public and private life sciences, including senior executive and CFO roles, and will support the company's progress toward potential commercialization of therapies for immune-mediated diseases. The filing does not disclose any financial results or performance metrics, so no period-over-period comparisons are available.

• · Ms. Deptula-Hicks currently serves as acting CFO of Normunity Inc., a clinical-stage cancer biotech.
• · She previously served as CFO of F-star Therapeutics, Inc.
• · Aldeyra's product candidates include RASP modulators ADX-248, ADX-246, and reproxalap (for dry eye disease and allergic conjunctivitis), and ADX-2191 (intravitreal methotrexate for primary vitreoretinal lymphoma and retinitis pigmentosa).

10-06-2026

Allegiant Travel Company announced a private offering of $650 million aggregate principal amount of 7.125% Senior Secured Notes due 2031 at an offering price of 99.479% of par. The offering size was increased by $150 million from the previously announced $500 million. The notes are expected to be issued on June 24, 2026, subject to customary closing conditions.

• · The offering size was increased by $150M from the initially announced $500M to $650M.
• · The Notes are being offered at 99.479% of principal amount.
• · The offering is private, not registered under the Securities Act, relying on Rule 144A and Regulation S.
• · The Notes are expected to be issued on June 24, 2026.

10-06-2026

Uranium Energy Corp. filed a DEFA14A (definitive additional proxy materials) with the SEC on June 10, 2026, providing supplemental soliciting materials related to its upcoming shareholder meeting. The filing does not contain any new financial results or operational updates, but serves as a procedural disclosure under Rule 14a-1. No fee was required for this filing.

• · Filing type is DEFA14A (Definitive Additional Proxy Materials).
• · Filed on June 10, 2026.
• · No fee was required for this filing.
• · The filing is supplemental to the proxy statement and does not contain standalone financial or operational data.

10-06-2026

FAS Wealth Partners, Inc. filed its 13F-HR for the quarter ended March 31, 2026, reporting total holdings of approximately $1.6059 billion across 511 positions. The portfolio is heavily weighted toward ETFs, with top holdings including Invesco S&P 500 Equal Weight ETF ($91.7M), iShares EAFE Growth ETF ($51.7M), and American Century US Large Cap Value ETF ($55.0M). The filing shows a diversified strategy with significant exposure to U.S. equities, international equities, and fixed income.

• · Top 10 holdings account for approximately 30% of total portfolio value.
• · Largest single holding is Invesco S&P 500 Equal Weight ETF at $91.7M (477,901 shares).
• · Significant positions in iShares EAFE Growth ETF ($51.7M) and iShares EAFE Value ETF ($19.4M).
• · The portfolio includes 4 shares of Berkshire Hathaway Class A valued at $2.87M.
• · Holdings include options: 400 call options on Amazon and 2,500 call options on Exxon Mobil, and 600 put options on Broadcom.
• · The filing includes a small position in iShares Global REIT ETF of only $19.

10-06-2026

Einride AB, a global leader in autonomous and electric freight, completed its business combination with Legato Merger Corp. III, approved by Legato shareholders on June 4, 2026. The transaction valued Einride at a pre-money equity value of approximately $1.35 billion and included an oversubscribed $113 million PIPE financing supported by new and existing investors. Einride's American depositary shares and warrants will begin trading on Nasdaq under the symbols "ENRD" and "ENRDW" on June 10, 2026.

• · Einride was founded in 2016.
• · The business combination was approved by Legato shareholders at an extraordinary general meeting on June 4, 2026.
• · The PIPE was supported by new and existing investors, including Stockholm-based EQT Ventures and a global asset management company based on the West Coast of the United States.
• · TD Cowen served as lead financial and capital markets advisor to Einride and lead placement agent on the PIPE.
• · BTIG, LLC served as capital markets advisor to Legato and as co-placement agent on the PIPE.
• · Legal counsel for Einride was provided by DLA Piper LLP (US), Advokatfirma DLA Piper Sweden KB, and Conyers Dill & Pearman LLP.
• · Legal counsel for Legato included Graubard Miller, Lindskog Malmström Advokatbyrå AB, and Appleby (Cayman) Ltd.
• · Greenberg Traurig, LLP served as legal counsel to the placement agents.
• · Einride serves customers across North America, Europe, and the Middle East.

10-06-2026

American Ventures Acquisition Corp. I filed an S-1 registration statement on June 9, 2026, for an initial public offering (IPO) as a blank check company. The filing details redemption rights for public stockholders upon completion of a business combination, with an anticipated trust account value of $5.00 per public share. However, the filing also includes a limitation that stockholders holding 15% or more of shares sold in the offering are restricted from redeeming more than that threshold without prior consent, which could reduce liquidity for large holders.

• · The filing is under SEC file number 333-296656.
• · The company is incorporated in Florida and classified under SIC 6770 (Blank Checks).
• · Redemption rights can be exercised via stockholder vote or tender offer, with tender offers required to remain open for at least 20 business days.
• · If stockholder approval is required, a majority of votes entitled to be cast is needed for approval.
• · The company may raise additional funds through equity-linked securities or debt to meet minimum cash requirements.
• · The limitation on redemption for holders of 15% or more of shares is designed to prevent large stockholders from blocking business combinations.

10-06-2026

RemSleep Holdings Inc. (RMSL) reported no revenue for Q1 2026, consistent with the prior-year period. Net loss widened significantly to $289,924 from $85,488 in Q1 2025, driven by a 76% increase in operating expenses to $231,348. Cash fell 59% to $87,953 from $214,514 at year-end 2025, and stockholders' equity turned negative at ($122,551) versus $32,062 at December 31, 2025, reflecting ongoing cash burn and operating losses.

• · Inventory increased 52% to $70,356 from $46,304 at year-end 2025.
• · Accounts payable rose 51% to $173,357 from $114,761.
• · The company issued 35,419,997 shares of common stock for note payable principal and accrued interest, valued at $135,311.
• · Derivative liability increased to $78,038 from $63,920 at December 31, 2025.
• · Accumulated deficit grew to $18,580,980 from $18,291,056.

10-06-2026

Rocket Companies upsized and priced a private offering of $900M in 6.125% senior notes due 2031 and $600M in 6.500% senior notes due 2034. The proceeds will be used to repay existing 2.875% notes due 2026 and 5.250% notes due 2028, along with other indebtedness. The offering is expected to close on June 16, 2026, with redemptions conditioned on closing.

• · Redemption price for both series of existing notes is 100.0% of principal plus accrued interest.
• · Redemption of 2026 notes is expected on or about June 19, 2026; 2028 notes on or about July 9, 2026.
• · Each redemption is conditioned on the closing of the new offering.
• · The new notes are being offered only to QIBs under Rule 144A and non-U.S. persons under Regulation S.

10-06-2026

VolitionRX Ltd (VNRX) priced a $4.6 million public offering on June 7, 2026, issuing 2,960,000 shares and warrants for up to 1,480,000 shares at a combined price of $1.55 per share. The offering includes participation from new and existing investors, with potential additional gross proceeds of up to $2.3 million from warrant exercises, though no assurance of exercise is given. The offering is expected to close on June 9, 2026.

• · The offering is being conducted under an effective shelf registration statement on Form S-3 (File No. 333-283088), filed with the SEC on November 8, 2024, and declared effective on April 18, 2025.
• · Each warrant has an exercise price of $1.55 per share, is exercisable immediately upon issuance, and expires five years after issuance.
• · Maxim Group LLC is the sole placement agent, and the offering is expected to close on June 9, 2026.
• · The company cautions that no assurance can be given that any warrants will be exercised.
• · VolitionRX is a multinational epigenetics company focused on developing blood tests for cancer and NETosis-related diseases like sepsis.

10-06-2026

News Corp filed an 8-K on June 10, 2026, disclosing its stock repurchase program authorization of up to $1 billion in aggregate of Class A and Class B common stock. The company provided daily transaction disclosures to the Australian Securities Exchange as required, with copies attached as exhibits. The filing includes forward-looking statements regarding the intent to repurchase shares from time to time.

• · The repurchase program covers both Class A common stock (NWSA) and Class B common stock (NWS).
• · Disclosures to the ASX are made on a daily basis for any transactions under the program.
• · The company also discloses repurchase information in its quarterly and annual reports.

10-06-2026

Reborn Coffee, Inc. announced the appointment of Jung Jae Lim as Chief Executive Officer, effective immediately, following the departure of Jay Kim as Co-Chief Executive Officer on June 4, 2026. The Board expressed confidence in Mr. Lim's leadership and stated the transition will not impact operations, expansion plans, franchise development, or financial reporting. No financial figures or performance metrics were disclosed in the filing.

• · Jung Jae Lim had served as Co-Chief Executive Officer and Director since March 2026 before assuming full CEO role.
• · The Board affirmed no impact on day-to-day operations, domestic/international expansion, franchise development, or financial reporting obligations.
• · The filing includes forward-looking statements cautioning about risks including the Company's ability to continue as a going concern due to recurring net losses.

10-06-2026

Metagenomi Therapeutics, Inc. (MGX) announced the resignation of board member Brian C. Thomas, Ph.D., effective June 9, 2026, with no disagreement cited. At the same time, the company held its 2026 annual meeting, where stockholders elected Juergen Eckhardt and Eric Bjerkholt as Class II directors and ratified PricewaterhouseCoopers LLP as the independent auditor for fiscal 2026. The meeting had a quorum of 19,116,207 shares (50.8% of outstanding shares), but the director elections saw significant broker non-votes (10,382,607) and relatively low 'for' votes, indicating potential shareholder disengagement.

• · The director election had 10,382,607 broker non-votes for both nominees, representing 54.3% of the quorum shares.
• · Eric Bjerkholt received 8,251,289 'for' votes (94.5% of votes cast excluding broker non-votes), while Juergen Eckhardt received 7,296,718 'for' votes (83.5% of votes cast excluding broker non-votes).
• · Ratification of PricewaterhouseCoopers LLP passed overwhelmingly with 18,483,295 'for' votes (99.7% of votes cast).
• · The record date for the annual meeting was April 13, 2026, and the proxy statement was filed on April 27, 2026.

10-06-2026

First Nebraska Trust Co filed its quarterly 13F-HR report with the SEC for the period ended March 31, 2025, disclosing its U.S. equity holdings. The firm held a diversified portfolio of approximately 190 positions with total disclosed market value of about $1.01 billion. The largest positions include Sysco Corp (~$198M), Apple Inc (~$62.6M), and Berkshire Hathaway Class B (~$49.9M), with no single position exceeding 20% of the portfolio, reflecting a broadly diversified institutional strategy.

• · The filing was signed by Scott A. Wendt, Vice President & Chief Investment Officer, on June 9, 2026.
• · Top 10 holdings by value represent roughly 40% of the total portfolio.
• · The portfolio contains a mix of common stocks, ETFs (iShares, SPDR, Vanguard, Invesco, WisdomTree), and a few non-U.S. companies via ADRs (Taiwan Semiconductor, TotalEnergies, Novartis, Diageo).
• · No holdings had shares subject to shared or no voting authority; all positions are listed with sole voting/investment discretion.
• · The filing includes 190 reportable positions on the Information Table.

10-06-2026

P3 Health Partners Inc. held its 2026 Annual Meeting on June 9, 2026, where all four proposals were approved. The three Class II director nominees (Amir Bacchus, Mark Thierer, Lawrence B. Leisure) were elected, and shareholders ratified BDO USA as auditor, approved executive compensation on an advisory basis, and authorized the issuance of up to 3,341,130 shares upon exercise of warrants held by VBC Growth SPV 5, LLC.

• · Broker non-votes were 425,510 for all director elections and proposals 1, 3, and 4.
• · Proposal 2 (ratification of auditor) had no broker non-votes and only 224 abstentions.
• · The record date for the Annual Meeting was April 10, 2026.

10-06-2026

Mobix Labs, Inc. provided a business update on June 9, 2026, detailing ongoing negotiations for a potential acquisition of Vision Aerial, a planned stockholder meeting in July 2026 with several proposals, and the settlement of two lawsuits and approximately $3.74 million in debt. However, the company cautioned that no definitive agreements have been reached for the Vision Aerial acquisition or any financing, and there is no assurance that the stockholder meeting will occur or that proposals will be approved.

• · The company expects to file a registration statement on Form S-1 to register the resale of approximately 3,300,000 shares for Kips and an aggregate of approximately 1,239,613 shares for five other selling stockholders.
• · The stockholder meeting in July 2026 will seek approval for: (1) issuance of shares to Kips from the May 19, 2026 transaction; (2) amendment to certificate of incorporation to remove restrictions on Class B common stock issuance; (3) increase in shares under the equity incentive plan; (4) issuance of shares for future fundraising and acquisitions.
• · The company has not yet filed preliminary or definitive proxy materials for the stockholder meeting.
• · The company expects to seek additional capital for potential M&A, working capital, and general corporate purposes, but no definitive agreements exist.
• · The company settled two lawsuits and satisfied approximately $3.74 million of debt liabilities.

10-06-2026

Hut 8 Corp. subsidiary Beacon Point DC LLC completed a $4.25 billion private offering of 6.129% Senior Secured Notes due 2042 to finance the development of a 352 MW data center in Nueces County, Texas, which will be leased to a high-investment-grade tenant (rated AA- or higher). The notes bear interest at 6.129% per annum, mature on November 30, 2042, and include amortization beginning May 30, 2030. The offering provides substantial capital for the project, but the high interest rate and long-term debt create significant fixed obligations, and the project's success depends on timely construction and tenant performance.

• · The Notes were issued at 100% of principal amount and will amortize semi-annually beginning May 30, 2030.
• · Interest on the Notes is payable semi-annually on May 30 and November 30, starting November 30, 2026.
• · The Issuer may redeem the Notes at make-whole price before May 30, 2042, and at 100% of principal after that date.
• · Upon a Data Center Lease Termination Event, the Issuer may redeem all or part of the Notes at 100% of principal plus accrued interest.
• · If the Debt Service Coverage Ratio falls below 1.1:1.0 after the Initial Commencement Date, the Issuer may redeem a portion of the Notes to restore the ratio to approximately 1.1:1.0.
• · The Indenture includes covenants limiting additional indebtedness, dividends, investments, liens, asset sales, and affiliate transactions.
• · Upon a change of control, the Issuer must offer to repurchase the Notes at 101% of principal plus accrued interest.
• · Upon certain asset sales or a Data Center Lease Termination Default, the Issuer must offer to repurchase the Notes at 100% of principal plus accrued interest.
• · The tenant is described as a high-investment-grade company rated AA- or higher.

10-06-2026

Vitesse Energy, Inc. held its Annual Meeting on June 5, 2026, where stockholders elected eight directors and ratified Deloitte & Touche LLP as the independent auditor for fiscal year 2026. All director nominees were elected, though Joseph S. Steinberg received the lowest support with over 3 million votes against, while Gary D. Reaves received the highest support. The ratification of Deloitte & Touche passed with overwhelming approval, with over 29 million votes in favor.

• · Total shares outstanding and voting power not disclosed, but broker non-votes were 7,029,180 for each director election.
• · Proposal 2 (auditor ratification) had no broker non-votes, with 29,213,741 votes for, 821,700 against, and 167,487 abstained.
• · Joseph S. Steinberg received the most votes against (3,062,853) among director nominees, while Gary D. Reaves received the most votes for (22,032,901).

10-06-2026

SMITH MIDLAND CORP reported a mixed first quarter for fiscal 2026. While total revenue declined 5% year-over-year to $21.6M (from $22.7M) due to a significant drop in barrier rentals, product sales grew 29% and shipping and installation revenue rose 58%. Net income slumped 60% to $1.3M from $3.3M, reflecting a lower gross margin. Cash from operations improved to $3.1M from $2.2M, and total assets increased to $92.2M.

• · Basic EPS fell to $0.25 from $0.63, diluted EPS to $0.25 from $0.62.
• · Cost of sales increased to $17.3M from $15.7M, while gross profit dropped to $4.3M from $7.0M (gross margin declined from 30.7% to 19.9%).
• · Cash and cash equivalents rose to $13.2M from $11.9M at year-end 2025.
• · Accounts payable - trade jumped to $8.3M from $5.5M, while deferred revenue (current) decreased to $0.9M from $1.1M.
• · Capital expenditures nearly tripled to $1.6M from $0.6M in the prior-year quarter.
• · Non-cash investing activity: capital expenditures in accounts payable were $0.9M.
• · Unbilled trade receivables (contract assets) rose to $1.8M from $1.2M at year-end 2025.
• · Allowance for expected credit losses increased to $651,000 from $539,000.

10-06-2026

Enliven Therapeutics, Inc. filed a Certificate of Amendment to its Restated Certificate of Incorporation on June 9, 2026, increasing total authorized shares to 210,000,000, consisting of 200,000,000 shares of Common Stock and 10,000,000 shares of Preferred Stock, each with a par value of $0.001. The amendment was duly adopted by the Board of Directors and stockholders.

• · Original certificate of incorporation filed under the name IMARA Inc. on January 26, 2016.
• · Amendment effective June 9, 2026.
• · Par value for both Common and Preferred Stock is $0.001 per share.

10-06-2026

Crown PropTech Acquisitions (SPAC) and Mkango Rare Earths Limited (MKAR) are proceeding with their previously announced business combination and plan to conduct investor meetings to support financing activities, including a contemplated private capital raise through equity, equity-linked, convertible, and/or debt securities. The filing includes an investor presentation (Exhibit 99.1) and forward-looking statements highlighting risks such as potential failure to complete the combination, market volatility, and geopolitical instability in Malawi and Poland. No specific financial figures or quantitative data are provided in this filing.

• · The SPAC is incorporated in the Cayman Islands and its redeemable warrants trade under the symbol CPTKW.
• · MKAR is a British Virgin Islands company and a wholly owned subsidiary of Mkango Resources Ltd. (British Columbia, Canada).
• · A registration statement on Form F-4 has been filed with the SEC and SEDAR+ in connection with the business combination.
• · The filing includes a detailed list of forward-looking risk factors, including risks related to rare earth material prices, geopolitical instability in Europe, Malawi, and Poland, and the ability to raise additional capital.

10-06-2026

Trane Technologies announced the appointment of Donny Simmons as Chief Operating Officer, effective July 1, 2026, reporting to Chair and CEO Dave Regnery. The move aligns leadership structure with the company's increased scale and expanding market opportunities, as Trane has nearly doubled annual revenue since 2020. No negative or flat performance metrics were disclosed in this filing.

• · Simmons previously served as Group President of the Americas region, overseeing commercial and residential HVAC, transport refrigeration, and life science solutions.
• · Simmons joined the company in 2001 and has led Commercial HVAC North America, EMEA, and several global industrial businesses.
• · Simmons has experience across general management, sales, manufacturing, and finance.

10-06-2026

J.Jill, Inc. reported a challenging first quarter for fiscal 2026, with net sales declining 6.0% YoY to $144.4 million and comparable sales falling 8.7%. Adjusted EBITDA dropped 38.8% to $16.7 million, and net income per diluted share fell to $0.31 from $0.76. However, the company reaffirmed its full-year outlook for flat to -2% net sales and Adjusted EBITDA of $70-75 million, while providing Q2 guidance of a narrower 1-3% sales decline, suggesting management expects gradual improvement.

• · Direct to consumer net sales represented 45.6% of total net sales in Q1 FY26, down 8.3% YoY.
• · SG&A decreased slightly to $89.7M from $91.1M, but as a percentage of sales increased to 62.1% from 59.3%.
• · Interest expense declined to $1.9M from $2.8M YoY.
• · Income tax provision was $2.5M vs $5.0M in Q1 FY25; effective tax rate rose to 35.2% from 29.8%.
• · The company opened 1 store and closed 2 stores in Q1 FY26, ending with 255 stores.
• · Inventory increased to $63.9M from $60.6M, including $5.5M of net tariff costs.
• · Free cash flow was an outflow of $1.1M vs an inflow of $2.6M in Q1 FY25.
• · Q2 FY26 outlook: net sales decline 1-3%, comparable sales decline 2-4%, gross margin decline ~100 bps, Adjusted EBITDA $18-20M.
• · Full year FY26 outlook reaffirmed: net sales flat to -2%, comparable sales -1% to -3%, gross margin decline ~50 bps, Adjusted EBITDA $70-75M, free cash flow $20M, capex $20-25M, net new stores 1-5.
• · Tariff assumptions: average 20% on inventory received before Feb 28, 2026; 10% on inventory received after Feb 28 through Q2; 15% thereafter. No tariff refund benefit assumed.
• · Second half unit inventory purchases positioned down mid-single digit percentage vs FY25.
• · Share repurchase authorization has $13.3M remaining as of May 2, 2026, expires Dec 6, 2026.
• · Quarterly dividend of $0.09 per share declared for both April 28 and July 8, 2026 payment dates.

10-06-2026

Teamshares CEO Michael Brown discussed the company's business model and growth plans on a podcast, highlighting its strategy as a tech-enabled acquirer of small to mid-size enterprises with a focus on employee ownership. The company reported $19 million in proforma adjusted EBITDA for 2025 and forecasts growth to $60 million in 2026 and $100 million by 2027, driven by a massive generational transition among small business owners. However, the filing contains forward-looking statements with significant risks, including potential failure to complete the business combination with Live Oak Acquisition Corp. V and the inability to achieve projected financial targets.

• · Teamshares acquires companies with EBITDA between $0.5M and $5M from retiring owners.
• · The company operates as a consolidated operating company, not an investment fund.
• · Over 75,000 businesses are actively for sale in Teamshares' software annually.
• · The business combination agreement was dated November 14, 2025.
• · Live Oak's public shareholders may redeem shares, posing a risk to the deal.
• · The filing includes a transcript generated by automated tools with possible errors.

10-06-2026

Tecnoglass Inc. announced a quarterly cash dividend of $0.15 per share for the second quarter of 2026, payable on July 31, 2026 to shareholders of record as of June 30, 2026. The filing does not include any financial results or period-over-period comparisons, so no negative or flat metrics are present.

• · Dividend record date: June 30, 2026
• · Dividend payment date: July 31, 2026
• · Filing includes cautionary language regarding forward-looking statements

10-06-2026

Chewy reported Q1 FY2026 net sales of $3.36B, up 7.7% YoY, with net income of $94.8M ($0.23 diluted EPS) compared to $62.4M ($0.15 diluted EPS) in the prior year. Gross margin improved 50 bps to 30.1%, and Adjusted EBITDA rose 31.4% to $253.1M. However, cash and cash equivalents declined sharply from $860.1M to $485.2M, driven by $200M in share repurchases and $174.8M in cash paid for an acquisition, while inventories increased 16.5% to $1.01B.

• · Share-based compensation expense was $66.9M in Q1 FY2026, down from $74.5M in Q1 FY2025.
• · Net cash provided by operating activities was $108.5M, up from $86.4M in the prior year.
• · Capital expenditures remained flat at $37.7M.
• · Total assets decreased slightly from $3.37B to $3.30B, while total liabilities increased from $2.87B to $2.88B.
• · The company acquired a business for $174.8M in cash during the quarter.
• · Weighted-average diluted shares outstanding decreased from 425.3M to 419.1M due to share repurchases.
• · Trade accounts payable increased to $1.31B from $1.22B, indicating potential supplier financing.

10-06-2026

Zion Oil & Gas Inc. announced on June 10, 2026, that field operations have commenced for the planned sidetrack phase of the Megiddo-Jezreel #2 well in Israel, with the company re-entering the well and drilling out a temporary plug. The drilling rig has been re-certified, recommissioned, and renamed JB-1 in honor of founder John Brown. No financial figures or performance metrics were disclosed in this operational update.

• · The company has re-entered the Megiddo-Jezreel #2 well and is drilling out a temporary plug.
• · After wellbore conditioning, horizontal sidetrack drilling will proceed.
• · The drilling rig has been re-certified and recommissioned per regulatory requirements.
• · The rig has been renamed JB-1 in honor of founder John Brown.

10-06-2026

SLM Corporation furnished a presentation to the SEC via Form 8-K that Co-President and CFO Pete Graham will discuss at the Morgan Stanley U.S. Financials Conference on June 10, 2026. The presentation was posted on the company's investor relations website. The filing contains no specific financial data or performance updates.

10-06-2026

Core & Main, Inc. reported net sales of $1,910M for Q1 FY26 (ended May 3, 2026), essentially flat versus $1,911M in Q1 FY25. Net income attributable to Core & Main increased 8.0% to $108M from $100M, driven by a 2.0% improvement in gross profit to $520M and lower interest expense. However, sales in the pipes, valves & fittings category declined 1.8% to $1,274M, and storm drainage sales fell 5.8% to $278M, partially offset by growth in fire protection (+17.1%) and smart utility products (+7.8%). Cash and cash equivalents decreased sharply to $150M from $220M at the start of the period, primarily due to $88M in share repurchases and $42M in tax receivable agreement payments.

• · Net cash provided by operating activities was $82M in Q1 FY26, up from $77M in Q1 FY25.
• · Capital expenditures were $14M in Q1 FY26, compared to $13M in the prior-year period.
• · Total assets increased to $6,324M as of May 3, 2026 from $6,085M as of February 1, 2026.
• · Long-term debt remained relatively stable at $2,120M (May 3, 2026) vs $2,124M (Feb 1, 2026).
• · The company repurchased 1,773,703 Class A shares in Q1 FY26 for $88M, compared to 837,268 shares for $39M in Q1 FY25.
• · Interest expense decreased to $27M in Q1 FY26 from $30M in Q1 FY25.
• · Provision for income taxes was $37M in Q1 FY26, up from $36M in Q1 FY25.

10-06-2026

Bread Financial Holdings, Inc. filed an 8-K on June 10, 2026, containing a press release (Exhibit 99.1) with a performance update for the period ended May 31, 2026. The filing is a Regulation FD disclosure; the press release was not filed for Section 18 Exchange Act purposes. The actual performance figures are not included in this 8-K text, only the notice of the press release.

• · Filing type is 8-K under items 7.01 (Regulation FD Disclosure) and 9.01 (Financial Statements and Exhibits).
• · The performance update press release is attached as Exhibit 99.1 but its content is not included in this filing text.
• · The press release is furnished, not filed, for purposes of Section 18 liability.
• · Company headquarters located at 3095 Loyalty Circle, Columbus, Ohio 43219.

10-06-2026

Cullinan Therapeutics announced updated clinical data from its Phase 1 OUTRACE trials for CLN-978 in treatment-refractory rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), as well as initial data from a Phase 1b/2a trial for velinotamig in SLE conducted by Genrix in China. Results showed encouraging efficacy and safety signals in heavily pre-treated patients, including a DAS28-ESR remission in RA and complete renal responses in SLE patients, though data remain early with small sample sizes and subject to change as trials continue.

• · A CLN-978-treated RA patient refractory to rituximab achieved DAS28-ESR remission: baseline score 4.0 dropped to 2.2 at week four, maintained through week eight, with rapid reduction in RA-associated autoantibodies.
• · First three SLE patients on multi-dose CLN-978 showed safety consistent with prior RA cohort; no new safety signals.
• · SLE patients with nephritis showed rapid improvement in proteinuria, supporting planned lupus nephritis Phase 2a expansion starting early 2027.
• · For velinotamig, both SLE patients achieved complete renal response; SLEDAI-2K scores dropped from 16 to 0 and from 14 to 2 at week eight.
• · No cytokine release syndrome or ICANS observed with velinotamig in these two patients.
• · Additional multi-dose data expected: CLN-978 RA in Q3 2026, CLN-978 SLE in Q4 2026, velinotamig SLE data from Genrix in Q4 2026.
• · Cullinan plans to initiate a Phase 1/2a trial for velinotamig in autoimmune cytopenias (ITP and AIHA) in Q1 2027.

10-06-2026

Incannex Healthcare Inc. announced receipt of A$6,039,162.43 (approximately A$6.0 million) under the Australian Government's R&D Tax Incentive Program for FY25, with an additional approximately A$5.1 million expected later in 2026, bringing total expected non-dilutive funding to more than A$11.1 million in 2026. The proceeds strengthen the company's balance sheet and financial flexibility without issuing shares or taking on debt, supporting clinical programs including IHL-42X and PSX-001 as well as an active share repurchase program. No negative or flat metrics were reported in this filing.

• · The company's lead clinical program IHL-42X is an oral fixed-dose combination of dronabinol and acetazolamide for obstructive sleep apnea, with the DReAMzz study recently commenced.
• · PSX-001 is an oral synthetic psilocybin treatment for generalized anxiety disorder, approved for Phase 2 clinical development.
• · IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate for inflammatory conditions such as rheumatoid arthritis, in Phase 2 development.
• · The company states it has a debt-free balance sheet and believes the market significantly undervalues its balance sheet, clinical progress, and value creation opportunities.